| | Business Summary | | Heska
Corporation
discovers,
develops,
manufactures
and
markets
companion
animal
health
products.
In
addition
to
its
pharmaceutical,
vaccine
and
diagnostic
products,
the
Company
also
sells
veterinary
diagnostic
and
patient
monitoring
instruments
and
offers
diagnostic
services
in
the
United
States
and
Europe
to
veterinarians.
Its
primary
manufacturing
subsidiary,
Diamond
Animal
Health,
Inc.,
manufactures
some
of
its
companion
animal
products
and
food
animal
vaccine
and
pharmaceutical
products,
which
are
marketed
and
distributed
by
third
parties.
Allercept,
Allercept
E-Screen,
Flu
Avert
I.N.,
Heska,
Vet/OX,
Vet/ECG,
Vet/IV,
Chem-Elite
and
Solo
Step
are
trademarks
of
the
Company.
Heska
sells
a
variety
of
companion
animal
health
products.
These
include
diagnostic,
vaccine
and
pharmaceutical
products.
The
Company
also
offers
a
broad
line
of
veterinary
diagnostic,
monitoring
and
other
Instruments. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Heska
Corp.
discovers,
develops,
manufactures
and
markets
companion
animal
health
product
through
two
full
scale
FDA
licensed
manufacturing
facilities,
and
provides
diagnostic
products
in
the
U.S.
and
U.K.
For
the
six
months
ended
6/30/01,
revenues
fell
24%
to
$21.9
million.
Net
loss
fell
21%
to
$9.2
million.
Revenues
reflect
the
absence
of
the
proceeds
from
the
sale
of
business.
Lower
loss
reflects
increased
sales
of
the
higher
margin
proprietary
PVD
products. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Grieve, Ph.D., 49
Chairman,
CEO | $271K | $213K | James Fuller, 56
Pres
and COO | 258K | -- | Ronald Hendrick, 55
CFO,
Exec. VP, Sec. | 192K | -- | Guisseppe Miozzari, Ph.D., 54
Managing
Director in Heska Europe | 189K | 70K | Dan Stinchcomb, Ph.D., 47
Exec.
VP- R&D | 183K | -- | | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/h/hska.gif)